ValuEngine downgraded shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) from a hold rating to a sell rating in a research note released on Tuesday morning.

OXFD has been the subject of a number of other research reports. Zacks Investment Research lowered Oxford Immunotec Global PLC from a hold rating to a sell rating in a report on Wednesday, August 30th. Cowen and Company reissued a buy rating and issued a $19.00 target price on shares of Oxford Immunotec Global PLC in a report on Thursday, September 28th. BTIG Research initiated coverage on Oxford Immunotec Global PLC in a report on Thursday, September 28th. They issued a buy rating and a $21.00 target price for the company. Finally, Piper Jaffray Companies reissued a buy rating and issued a $26.00 target price on shares of Oxford Immunotec Global PLC in a report on Thursday, August 3rd. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. Oxford Immunotec Global PLC currently has an average rating of Hold and an average price target of $19.75.

Oxford Immunotec Global PLC (NASDAQ OXFD) remained flat at $$13.25 during trading hours on Tuesday. The company had a trading volume of 191,572 shares, compared to its average volume of 144,654. The company has a debt-to-equity ratio of 0.38, a current ratio of 4.72 and a quick ratio of 2.51.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last posted its earnings results on Tuesday, August 1st. The company reported ($0.32) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.32). The business had revenue of $26.10 million during the quarter, compared to analyst estimates of $25.05 million. Oxford Immunotec Global PLC had a negative return on equity of 38.42% and a negative net margin of 45.74%. The company’s quarterly revenue was up 35.9% compared to the same quarter last year. During the same quarter last year, the company earned ($0.29) EPS. equities research analysts predict that Oxford Immunotec Global PLC will post -2.11 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/oxford-immunotec-global-plc-oxfd-cut-to-sell-at-valuengine/1676848.html.

In other news, Director Richard A. Sandberg sold 3,000 shares of the firm’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $13.35, for a total value of $40,050.00. Following the transaction, the director now directly owns 17,778 shares in the company, valued at approximately $237,336.30. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Peter Wrighton-Smith sold 55,000 shares of the firm’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $16.78, for a total value of $922,900.00. The disclosure for this sale can be found here. In the last three months, insiders sold 93,110 shares of company stock valued at $1,563,564. Corporate insiders own 8.11% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. Nationwide Fund Advisors boosted its stake in shares of Oxford Immunotec Global PLC by 1.9% in the 1st quarter. Nationwide Fund Advisors now owns 13,765 shares of the company’s stock worth $213,000 after buying an additional 254 shares during the last quarter. American International Group Inc. boosted its stake in shares of Oxford Immunotec Global PLC by 7.1% in the 1st quarter. American International Group Inc. now owns 13,668 shares of the company’s stock worth $212,000 after buying an additional 904 shares during the last quarter. Parkwood LLC boosted its stake in shares of Oxford Immunotec Global PLC by 12.9% in the 2nd quarter. Parkwood LLC now owns 12,799 shares of the company’s stock worth $215,000 after buying an additional 1,465 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of Oxford Immunotec Global PLC by 8.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,631 shares of the company’s stock worth $313,000 after buying an additional 1,500 shares during the last quarter. Finally, Voya Investment Management LLC boosted its stake in shares of Oxford Immunotec Global PLC by 16.0% in the 2nd quarter. Voya Investment Management LLC now owns 13,345 shares of the company’s stock worth $224,000 after buying an additional 1,845 shares during the last quarter. Hedge funds and other institutional investors own 79.21% of the company’s stock.

About Oxford Immunotec Global PLC

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.